Response of Patients with Taxane-Refractory Advanced Urothelial Cancer to Enfortumab Vedotin, a Microtubule-Disrupting Agent

Figure 2

Clinical courses of two cases who treated with taxane-based chemotherapy and enfortumab vedotin. The details of the clinical course are described in the main text. Both patients are alive, and EV treatment is ongoing. Yellow arrows indicate metastatic lesions. Abbreviations: GCa: gemcitabine and carboplatin combination chemotherapy; GC: gemcitabine and cisplatin combination chemotherapy; MVAC: methotrexate, vinblastine, doxorubicin, and cisplatin combination chemotherapy; Pem: pembrolizumab; EV: enfortumab vedotin; PG: paclitaxel and gemcitabine combination chemotherapy; PN: paclitaxel and nedaplatin combination chemotherapy; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease.

(a)

(b)